Autolus Therapeutics plc American Depositary Share (AUTL)
AUTL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/0001730463-26-000038-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AUTL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United Kingdom |
| IPO year | 2018 |
| SEC CIK | 0001730463 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | United Kingdom |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $75.4M |
| Net income | -$287.5M |
| Operating income | -$270.5M |
| Net margin | -381.4% |
| Operating margin | -358.9% |
| Revenue growth | +644.9% |
| Cash | $104.1M |
| Total assets | $589.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Accordingly, management has concluded that there are no conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued." | 10-Q 2026-11-10 |
| Cash and burn | $245.4M cash; operating cash flow -$44.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 266,340,330 (2026-11-09); 266,143,286 a year earlier; 173,989,157 three years earlier. | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-09-14 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Reading, United Kingdom; changed auditors 1 time in 24 months | 8-K 4.01 2026-04-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $16K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $41.2M | -$55.1M | -$18.5M | $245.4M | No debt tags | $137.4M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $45.7M | -$39.1M | -$25.1M | $171.4M | No debt tags | $117.4M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $26.2M | -$71.6M | -$65.3M | $130.9M | No debt tags | $92.6M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $24.3M | -$90.3M | -$67.3M | $104.1M | No debt tags | $75.4M | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | $21.2M | -$79.1M | -$67.9M | $86.1M | No debt tags | $51.1M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $20.9M | -$47.9M | -$72.8M | $123.8M | No debt tags | $29.9M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $9.0M | -$70.2M | -$75.6M | $95.8M | No debt tags | $9.0M | 10-Q 2025-05-08 |
| Q4 2024 2024-12-31 | $29K | -$27.6M | -$37.9M | $227.4M | No debt tags | $10.1M | 10-K 2026-03-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-22 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
Source: SEC EDGAR submissions feed, 343 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.6% |
| 1 month | -27.8% |
| 3 months | -47.3% |
| Year to date | -41.2% |
| 1 year | -8.6% |
| From 52-week high | -53.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KYTX | Kyverna Therapeutics Inc. | $4.76 | -5.74% | $300.9M |
| IPSC | Century Therapeutics Inc. | $1.64 | -0.61% | $297.8M |
| TRXB | TRex Bio Inc. | $10.77 | -21.21% | $295.6M |
| AGMB | AgomAb Therapeutics NV | $5.97 | -6.13% | $294.0M |
| PROK | ProKidney Corp. | $1.04 | -0.48% | $314.5M |
| EIKN | Eikon Therapeutics Inc. | $5.38 | -9.95% | $291.8M |
| SCTX | Scribe Therapeutics Inc. | $15.37 | -6.05% | $291.1M |
| XFOR | X4 Pharmaceuticals Inc. | $2.83 | -9.29% | $289.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier